Scientists that discovered a life-saving drug to treat cancer patients with a faulty gene are marking a special anniversary, and looking back at the impact their work has had around the world.

Professor Ruth Plummer, Director of the Cancer Research UK Newcastle Centre, and Professor Herbie Newell, Emeritus Professor of Cancer Therapeutics at Newcastle University, were among the team, funded ...

Recent FDA approvals have included Rubraca (rucaparib), which was approved in 2020 for patients with metastatic castration-resistant prostate cancer that expresses a BRCA mutation, and Lynparza ...

However, the approaches within these trials resemble the Olaparib trials. Rucaparib and Niraparib are being investigated in platinum sensitive ovarian cancers as a maintenance therapy (NCT01968213 ...

A drug used against cancer could also be effective against severe coronavirus infection.

While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change that. At ASCO, AZ ...

PARP inhibitors, which are now used as a first-line management in newly diagnosed individuals, include the FDA-approved olaparib, as well as rucaparib and niraparib. Ovarian cancer is the eighth ...

Rucaparib in the TRITON3 trial showed superior progression-free survival compared to standard treatments, highlighting its efficacy in targeted patient populations. Genetic profiling is crucial for ...

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer TA1007 17 September 2024 17 September 2024 ...